SCHEMBL2388720

SCHEMBL2388720

O=C(c1ccc(-c2ccccc2)c(C2CC2)c1)N1CCC(c2cccnc2)C1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.61
ROCK2 O75116 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
ATM Q13315 1/20 0.52
SPR P35270 1/20 0.52
HSD11B1 P28845 1/20 0.48
SCD5 Q86SK9 3/20 0.48
SCD O00767 2/20 0.48
CYP46A1 Q9Y6A2 1/20 0.48
PARP14 Q460N5 1/20 0.45
PARP10 Q53GL7 1/20 0.45
PROKR1 Q8TCW9 1/20 0.45
CYP2C9 P11712 1/20 0.44
SLC9A1 P19634 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
CCR5 P51681 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393040 0.92 NAMPT (0.58) NAMPTROCK2NPC1RAB9AATM
SCHEMBL2387066 0.90 NAMPT (0.64) NAMPTROCK2NPC1RAB9AATM
SCHEMBL2388346 0.88 NAMPT (0.58) NAMPTROCK2NPC1RAB9AATM
SCHEMBL2389098 0.88 NAMPT (0.56) NAMPTROCK2NPC1RAB9AATM
SCHEMBL2389808 0.87 NAMPT (0.58) NAMPTROCK2NPC1RAB9AATM
SCHEMBL2389112 0.87 NAMPT (0.59) NAMPTROCK2NPC1RAB9AATM
SCHEMBL2392419 0.87 NAMPT (0.59) NAMPTROCK2NPC1RAB9AATM
SCHEMBL2388247 0.86 ROCK2 (0.70) NAMPTROCK2NPC1RAB9AATM
SCHEMBL2388534 0.86 NAMPT (0.58) NAMPTROCK2NPC1RAB9AATM
SCHEMBL2388267 0.85 NAMPT (0.56) NAMPTROCK2NPC1RAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2375904-B1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME (US) 2014-05-28 EP claimed
EP-2375904-A1 BIARYL CARBOXAMIDES Merck Sharp & Dohme Corp. (US) 2011-10-19 EP claimed
US-20110230498-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. 2011-09-22 US claimed
WO-2010077624-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. (US) 2010-07-08 WO claimed
EP-2375904-B1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME (US) 2014-05-28 EP disclosed
US-8367679-B2 Biaryl carboxamides MERCK SHARP & DOHME CORP. (US) 2013-02-05 US disclosed
EP-2375904-A1 BIARYL CARBOXAMIDES Merck Sharp & Dohme Corp. (US) 2011-10-19 EP disclosed
US-20110230498-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. 2011-09-22 US disclosed
WO-2010077624-A1 BIARYL CARBOXAMIDES MERCK SHARP & DOHME CORP. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230498-A1 BIARYL CARBOXAMIDES PAFAH1B3, PAFAH1B2, FAAH2 NAMPT 2170/4885ROCK2 1766/4885NPC1 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.